LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
[RO−P(O)2−O−P(O)2−O−PO3]4− + H2O → [RO−P(O)2−O−PO3]3− + [HPO4]2− + H+ [RO−P(O)2−O−P(O)2−O−PO3]4− + H2O → [RO−PO3]2− + [HO3P−O−PO3]3− + H+ For ATP hydrolysis that takes place with the physiological concentrations of ATP, ADP, and inorganic phosphate (Pi) within the living cell, the change in Gibbs free energy is given by:
=== Reaction pathways === Diterpenes are commonly synthesized from the precursor molecule geranylgeranyl pyrophosphate (GGPP). GGPP's hydrocarbon backbone can be rearranged into different structures that may be further rearranged or added to in order to create precursors for different families of diterpenoid compounds. This precursor molecule may be synthesized through the mevalonic acid pathway or the deoxyxylulose pathway. These pathways produce isopentenyl pyrophosphate, which can be rearranged into GGPP. The cyclization of GGPP and the subsequent reorganizations into different precursors is controlled by a large family of enzymes known as diterpene syntheses (diTPS). To synthesize sugiol a plant must first synthesize GGPP through either of the previously mentioned pathways, (mevalonic acid or the deoxyxylulose pathway), then rearrange GGPP into the molecule mitiradiene. After formation of an intermediate compound abietatriene, a cytochrome P450 enzyme can then attach an oxygen molecule to the intermediate. This produces ferruginol, which can then be modified to sugiol by sugiol synthase. Sugiol may then be formed through the modification of ferruginol according to the following reaction driven by the enzyme sugiol synthase.
== Career == Sperti graduated from the University of Cincinnati in 1923. Shortly afterwards he was named Director of its Research Laboratory. His invention of an ultraviolet lamp to irradiate milk and add Vitamin D without changing the flavor was sold to General Foods for US$300,000. Sperti donated the entire amount to the University to continue basic research, and went on to develop a successful business line of ultraviolet sunlamps. He also invented the first practical technique for freeze-drying orange juice concentrate. He donated most of the money he received from 127 patents to the University of Cincinnati and the Institutum Divi Thomae, which he co-founded in 1935 in collaboration with the Archdiocese of Cincinnati, with the purpose of researching cancer. A cell derivative believed to stimulate healthy cell growth was discovered at the school by Stanley L. Baker, Ph.D., and was originally tested on burn victims. An accidental application of it resulted in a huge market as Preparation H. The primary active ingredient in his invention was a compound containing a live yeast cell derivative (LYCD), which Sperti named Bio-Dyne. The Food and Drug Administration later discovered clinical testing irregularities in the use of LYCD, and it was removed from the formulation sold in the United States. There are stories that the original Preparation H was used to treat burns. The Canadian and European versions of Preparation H still contain the ingredient.
== Side effects == Common side effects are peeling, itching, redness, dryness, burning, and dermatitis. Benzoyl peroxide bleaches hair, clothes, towels, bedclothing, and the like. Prolonged exposure to natural or artificial sun light (UV rays) is not recommended because the gel may cause photosensitivity. Irritation due to benzoyl peroxide can be reduced by avoiding harsh facial cleansers and wearing sunscreen prior to sun exposure. Clinical studies have shown systemic absorption of clindamycin through topical application, in some cases leading to diarrhea, bloody diarrhea, and colitis. Reports of anaphylaxis were also seen. However, the sources of these reports were personal accounts without controls and of an unknown population, thus it is difficult to attribute their cause to the clindamycin/benzoyl peroxide gel.
Ian McCartney, Labour Party chairman at the time, said Galloway was the only Labour MP who "incited foreign forces to rise up against British troops". Tony Benn questioned why Galloway strove to remain in the Labour Party despite calling its leadership a "blood-splattered, lying, crooked group of war criminals". Benn added, "It put me off George Galloway in a fairly fundamental way". Following the 7 July 2005 London bombings, which killed 52 civilians, Galloway linked the attack to Western policies in the Middle East. He said Tony Blair and George W. Bush had "far more blood on their hands" than the terrorists who carried out the bombings, and called President Bush the world's "biggest terrorist".
Sources: en.wikipedia.org
== Combination hemoglobinopathies == A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity. Some examples of clinically significant combinations involving beta thalassemia include:
action potential The local change in voltage that occurs when the membrane potential of a specific location along the membrane of a cell rapidly depolarizes, such as when a nerve impulse is transmitted between neurons.
=== Signaling === D-Serine, synthesized in neurons by serine racemase from L-serine (its enantiomer), serves as a neuromodulator by coactivating NMDA receptors, making them able to open if they then also bind glutamate. D-serine is a potent agonist at the glycine site (NR1) of canonical diheteromeric NMDA receptors. For the receptor to open, glutamate and either glycine or D-serine must bind to it; in addition a pore blocker must not be bound (e.g. Mg2+ or Zn2+). Some research has shown that D-serine is a more potent agonist at the NMDAR glycine site than glycine itself. However, D-serine has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors through the glycine binding site on the GluN3 subunit.
=== Campaigning === Heseltine was not one to befriend and gossip with colleagues or backbenchers. He did not regard this as an insurmountable problem, as neither Heath nor Thatcher had been particularly "clubbable" either. From about the mid-1970s, he began a campaign of addressing local associations, sometimes using a helicopter to speak to several in one day. Heseltine had often had a reputation for being very cold and aloof with backbench MPs and party activists (Steven Norris said that after a visit to his constituency in 1983, local activists used a poster of Heseltine as a dartboard). However, in 1986–1990 he was a frequent visitor to local constituency dinners, although he usually attacked Labour rather than the Conservative government, and he used his wealth to afford a chauffeur and a helicopter. Heseltine campaigned in 100 constituencies in the 1987 election, attracting more publicity than many Cabinet ministers, although seldom mentioning Thatcher by name. During this period Heseltine enjoyed excellent relations with the media: among TV journalists he was in regular touch with Elinor Goodman of Channel 4 News (herself a former Haymarket employee), James Mates of ITN (son of his lieutenant Michael Mates) and John Cole, whilst among print journalists he was close to his old friend Anthony Howard (Deputy Editor of the Observer), Peter Jenkins, and especially close to Anthony Bevins of The Independent and the young Alastair Campbell of the Daily Mirror.
Sources: en.wikipedia.org
== Characteristics == The discovery of a new family of mesoporous molecular sieves in the early 1990s by Kuroda et al., known as KSW-1 and FSM-16, and by ExxonMobil, called M41S, opened new possibilities to prepare catalysts for reactions of relatively large molecules. The silicate wall of the pores is amorphous. Mesoporous silicates, such as MCM-41 and SBA-15 (the most common mesoporous silicates), are porous silicates with huge surface areas (normally ≥1000 m2/g), large pore sizes (2 nm ≤ size ≤ 20 nm) and ordered arrays of cylindrical mesopores with very regular pore morphology. The large surface areas of these solids increase the probability that a reactant molecule in solution will come into contact with the catalyst surface and react. The large pore size and ordered pore morphology allow one to be sure that the reactant molecules are small enough to diffuse into the pores.
=== Industry and legal actions === DuPont has used PFOA for over 50 years at its Washington Works plant. Area residents sued DuPont in August 2001 and claimed DuPont released PFOA in excess of their community guideline of 1 part per billion resulting in lower property values and increased risk of illness. The class was certified by Wood Circuit Court Judge George W. Hill. As part of the settlement, DuPont has paid for blood tests and health surveys of residents believed to be affected. Participants numbered 69,030 in the study, which was reviewed by three epidemiologists—the C8 Science Panel—to determine if any health effects are the likely result of exposure. On December 13, 2005, DuPont announced a settlement with the EPA in which DuPont would pay US$10.25 million in fines and an additional US$6.25 million for two supplemental environmental projects without any admission of liability. On September 30, 2008, Chief Judge Joseph R. Goodwin of the United States District Court for the Southern District of West Virginia denied the certification of a class of Parkersburg residents exposed to PFOA from DuPont's facility because they did not "show the common individual injuries needed to certify a class action". On September 28, 2009, Judge Goodwin dismissed the claims of those residents except for medical monitoring. By 2015, more than three thousand plaintiffs have filed personal-injury lawsuits against DuPont. In 2017, DuPont reached a $670.7 million cash settlement related to 3,550 personal injury lawsuits tied to PFOA contamination of drinking water in the Parkersburg area.
Serotonin (a neurotransmitter), synthesized by tryptophan hydroxylase. Melatonin (a neurohormone) is in turn synthesized from serotonin, via N-acetyltransferase and 5-hydroxyindole-O-methyltransferase enzymes. Kynurenine, to which tryptophan is mainly (more than 95%) metabolized. Two enzymes, namely indoleamine 2,3-dioxygenase (IDO) in the immune system and the brain, and tryptophan 2,3-dioxygenase (TDO) in the liver, are responsible for the synthesis of kynurenine from tryptophan. The kynurenine pathway of tryptophan catabolism is altered in several diseases, including psychiatric disorders such as schizophrenia, major depressive disorder, and bipolar disorder. Niacin, also known as vitamin B3, is synthesized from tryptophan via kynurenine and quinolinic acids. Auxins (a class of phytohormones) are synthesized from tryptophan. The disorder fructose malabsorption causes improper absorption of tryptophan in the intestine, reduced levels of tryptophan in the blood, and depression. In bacteria that synthesize tryptophan, high cellular levels of this amino acid activate a repressor protein, which binds to the trp operon. Binding of this repressor to the tryptophan operon prevents transcription of downstream DNA that codes for the enzymes involved in the biosynthesis of tryptophan. So high levels of tryptophan prevent tryptophan synthesis through a negative feedback loop, and when the cell's tryptophan levels go down again, transcription from the trp operon resumes.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.